Actively Recruiting
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Led by Yuhan Corporation · Updated on 2026-02-24
147
Participants Needed
19
Research Sites
296 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
CONDITIONS
Official Title
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed HER2-positive tumor (Dose Escalation Part)
- Mandatory provision of tumor tissue sample (all parts)
- At least one measurable lesion (Dose Expansion Part)
- Cohort 1: HER2-positive biliary tract cancer with prior gemcitabine- and/or cisplatin-based therapy
- Cohort 2: HER2-positive metastatic solid tumors excluding breast, gastric, gastroesophageal junction adenocarcinoma, and biliary tract cancer with no available standard therapies
You will not qualify if you...
- Uncontrolled central nervous system metastases
- Spinal cord compression
- Carcinomatous meningitis
- Acute coronary syndromes
- Heart failure
- Interstitial lung disease
- Pneumonitis
- History of a second primary cancer
- Human immunodeficiency virus (HIV)
- Active chronic hepatitis B
- Hepatitis C
- Systemic steroid therapy
- Autoimmune disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
2
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
3
Southern Oncology Clinical Research Unit
Adelaide, Australia
Actively Recruiting
4
Austin Health
Melbourne, Australia
Actively Recruiting
5
Breast Cancer Research Centre - WA
Perth, Australia
Withdrawn
6
Blacktown Hospital
Sydney, Australia
Actively Recruiting
7
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea, 13496
Actively Recruiting
8
Catholic University of Korea St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea, 16247
Actively Recruiting
9
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea, 16499
Actively Recruiting
10
Gyeongsang National University Hospital
Jinju, Gyeongsangnam-do, South Korea, 52727
Actively Recruiting
11
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea, 28644
Actively Recruiting
12
Gachon Gil University Medical Center
Incheon, South Korea, 21565
Actively Recruiting
13
Korea University Anam Hospital
Seoul, South Korea, 02841
Actively Recruiting
14
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
15
Severance Hospital, Yonsei University Health System
Seoul, South Korea, 03722
Actively Recruiting
16
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
17
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
18
The Catholic University of Korea, St. Mary's hospital
Seoul, South Korea, 06591
Actively Recruiting
19
Ulsan University Hospital
Ulsan, South Korea, 44437
Actively Recruiting
Research Team
C
Clinical Operation Team 1
CONTACT
J
Jiyong Park
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here